Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors

References

• Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179–204.
   PubMed Web of Science ®Google Scholar
• Reardon JT, Sancar A. Purification and characterization of Escherichia coli and human nucleotide excision repair enzyme systems. Methods Enzymol. 2006;408:189–213.
   PubMed Web of Science ®Google Scholar
• Wilson TE, Grawunder U, Lieber MR. Yeast DNA ligase IV mediates non-homologous DNA end joining. Nature. 1997;388(6641):495–498.
   PubMed Web of Science ®Google Scholar
• Grob P, Zhang TT, Hannah R, et al. Electron microscopy visualization of DNA-protein complexes formed by Ku and DNA ligase IV. DNA Repair (Amst). 2012;11(1):74–81.
   PubMed Web of Science ®Google Scholar
• Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18(1):134–147.
   PubMed Web of Science ®Google Scholar
• Liang L, Deng L, Chen Y, et al. Modulation of DNA end joining by nuclear proteins. J Biol Chem. 2005;280(36):31442–31449.
   PubMed Web of Science ®Google Scholar
• Truong LN, Li Y, Shi LZ, et al. Microhomology-mediated end joining and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc Natl Acad Sci USA. 2013;110(19):7720–7725.
   PubMed Web of Science ®Google Scholar
• Pearl LH, Schierz AC, Ward SE, et al. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015;15(3):166–180.
   PubMed Web of Science ®Google Scholar
• Manic G, Obrist F, Sistigu A, et al. Trial watch: targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol. 2015;2(4):e1012976.
   PubMed Web of Science ®Google Scholar
• Velic D, Couturier AM, Ferreira MT, et al. DNA damage signalling and repair inhibitors: the long-sought-after achilles’ heel of cancer. Biomolecules. 2015;5(4):3204–3259.
   PubMed Web of Science ®Google Scholar
• Chen T, Sun Y, Ji P, et al. Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene. 2015;34(31):4019–4031.
   PubMed Web of Science ®Google Scholar
• Herceg Z, Wang ZQ. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res. 2001;477(1–2):97–110.
   PubMed Web of Science ®Google Scholar
• Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16(1):2–9.
   PubMed Web of Science ®Google Scholar
• Thompson R, Eastman A. The cancer therapeutic potential of CHK1 inhibitors: how mechanistic studies impact on clinical trial design. Br J Clin Pharmacol. 2013;76(3):358–369.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Xue J, Sowin TJ, et al. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther. 2006;5(8):1935–1943.
   PubMed Web of Science ®Google Scholar
• Sanchez Y, Wong C, Thoma RS, et al. Conservation of the CHK1 checkpoint pathway in mammals: linkage of DNA damage to CDK regulation through CDC25. Science. 1997;277(5331):1497–1501.
   PubMed Web of Science ®Google Scholar
• Scorah J, McGowan CH. Claspin and CHK1 regulate replication fork stability by different mechanisms. Cell Cycle. 2009;8(7):1036–1043.
   PubMed Web of Science ®Google Scholar
• Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA. 2010;107(37):16090–16095.
   PubMed Web of Science ®Google Scholar
• Bahassi EM, Ovesen JL, Riesenberg AL, et al. The checkpoint kinases CHK1 and CHK2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene. 2008;27(28):3977–3985.
   PubMed Web of Science ®Google Scholar
• Hu J, Sun L, Shen F, et al. The intra-S phase checkpoint targets DNA2 to prevent stalled replication forks from reversing. Cell. 2012;149(6):1221–1232.
   PubMed Web of Science ®Google Scholar
• Bansbach CE, Bétous R, Lovejoy CA, et al. The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks. Genes Dev. 2009;23(20):2405–2414.
   PubMed Web of Science ®Google Scholar
• Sørensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase CHK1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005;7(2):195–201.
   PubMed Web of Science ®Google Scholar
• Gilad O, Nabet BY, Ragland RL, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010;70(23):9693–9702.
   PubMed Web of Science ®Google Scholar
• Laquente B, Lopez-Martin J, Richards D, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 2017;17(1):137.
   PubMed Web of Science ®Google Scholar
• Lau CC, Pardee AB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA. 1982;79(9):2942–2946.
   PubMed Web of Science ®Google Scholar
• Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem. 2004;91(2):223–231.
   PubMed Web of Science ®Google Scholar
• Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hCHK1. Cancer Res. 2000;60(8):2108–2112.
   PubMed Web of Science ®Google Scholar
• Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998;58(15):3248–3253.
   PubMed Web of Science ®Google Scholar
• Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res. 1996;2(5):791–797.
   PubMed Web of Science ®Google Scholar
• Thompson R, Meuth M, Woll P, et al. Treatment with the CHK1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells. Int J Oncol. 2012;40(1):194–202.
   PubMed Web of Science ®Google Scholar
• Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther. 2008;7(8):2394–2404.
   PubMed Web of Science ®Google Scholar
• Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol. 2009;76(1):208–214.
   PubMed Web of Science ®Google Scholar
• Montano R, Chung I, Garner KM, et al. Preclinical development of the novel CHK1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012;11(2):427–438.
   PubMed Web of Science ®Google Scholar
• Tse AN, Rendahl KG, Sheikh T, et al. CHIR-124, a novel potent inhibitor of CHK1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res. 2007;13(2 Pt 1):591–602.
   PubMed Web of Science ®Google Scholar
• Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7(9):2955–2966.
   PubMed Web of Science ®Google Scholar
• Walton MI, Eve PD, Hayes A, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010;9(1):89–100.
   PubMed Web of Science ®Google Scholar
• Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle. 2007;6(1):104–110.
   PubMed Web of Science ®Google Scholar
• Wayne J, Brooks T, Massey AJ. Inhibition of CHK1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. Oncotarget. 2016;7(51):85033–85048.
   PubMed Web of Science ®Google Scholar
• Bryant C, Rawlinson R, Massey AJ. CHK1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014;14:570.
   PubMed Web of Science ®Google Scholar
• Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–4288.
   PubMed Web of Science ®Google Scholar
• Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010;70(20):7970–7980.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708.
   PubMed Web of Science ®Google Scholar
• Oza V, Ashwell S, Almeida L, et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J Med Chem. 2012;55(11):5130–5142.
   PubMed Web of Science ®Google Scholar
• Labroli M, Paruch K, Dwyer MP, et al. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach–part 2. Bioorg Med Chem Lett. 2011;21(1):471–474.
   PubMed Web of Science ®Google Scholar
• King C, Diaz H, Barnard D, et al. Characterization and preclinical development of LY2603618: a selective and potent CHK1 inhibitor. Invest New Drugs. 2014;32(2):213–226.
   PubMed Web of Science ®Google Scholar
• Gazzard L, Appleton B, Chapman K, et al. Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. Bioorg Med Chem Lett. 2014;24(24):5704–5709.
   PubMed Web of Science ®Google Scholar
• Teng M, Zhu J, Johnson MD, et al. Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2ʹ,4ʹ-diols as novel and potent human CHK1 inhibitors. J Med Chem. 2007;50(22):5253–5256.
   PubMed Web of Science ®Google Scholar
• Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for CHK1 inhibition by UCN-01. J Biol Chem. 2002;277(48):46609–46615.
   PubMed Web of Science ®Google Scholar
• Seto T, Esaki T, Hirai F, et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013;72(3):619–627.
   PubMed Web of Science ®Google Scholar
• Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;73(3):539–549.
   PubMed Web of Science ®Google Scholar
• Daud AI, Ashworth MT, Strosberg J, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015;33(9):1060–1066.
   PubMed Web of Science ®Google Scholar
• Thomas BM, Kaufmann SH, Greer JM, et al. Phase I dose-escalation study of SCH 900776 in combination with cytarabine (Ara-C) in patients with acute leukemia. In: Blood. American Society of Hematology. Vol. 118. 2011. p. 1531.
   Google Scholar
• Calvo E, Braiteh F, Von Hoff D, et al. Phase I study of CHK1 inhibitor LY2603618 in combination with gemcitabine in patients with solid tumors. Oncology. 2016;91(5):251–260.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Kang JH, Smith D, et al. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Invest New Drug. 2016;34(5):625–635.
   PubMed Web of Science ®Google Scholar
• Hong D, Infante J, Janku F, et al. Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. J Clin Oncol. 2016;34(15):1764–1771.
   PubMed Web of Science ®Google Scholar
• Infante JR, Hollebecque A, Postel-Vinay S, et al. Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Vol 75 issue 15: AACR 106th Annual Meeting 2015; Philadelphia. 2015 Aug.
   Google Scholar
• Asaoka Y, Ijichi H, Koike K. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373(20):1979.
   PubMed Web of Science ®Google Scholar